Validation of rAAV-focused commercial opportunities
Lead Research Organisation:
University of Edinburgh
Department Name: Biomedical Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
Matthew Nolan (Principal Investigator) |
Description | We commissioned a market research report and an intellectual property report to address the feasibility of developing a business service for proving viral vectors for pre-clinical or clinical research. The market research report identified strong unmet pre-clinical demand and relatively low barriers to entering the market. The report identified a pathway to further develop the business idea. The intellectual property report indicated that key patents in the area are expired giving considerable freedom to operate. It also identified areas for future exploration and clarification. |
Exploitation Route | The results of the Pathfinder led us to focus on developing a local viral vector core facility, which is now fully operational, and collaboration with a biotech Synpromics. This collaboration has been supported by funding from IBioIC. |
Sectors | Healthcare Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |
Description | The study led us to focus on developing of external collaborations, which led to an IBioIC award with Synpromics. |
First Year Of Impact | 2016 |
Sector | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
Description | Synthetic Biology Accelerator grant. |
Amount | £245,589 (GBP) |
Organisation | IBioIC |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2017 |
End | 02/2019 |
Description | Collaboration with Synpromics |
Organisation | Synpromics |
Country | United Kingdom |
Sector | Private |
PI Contribution | Synpromics is a biotech company specialising in engineering synthetic promoters. We have established a collaboration with Synpromics to develop virus-based tools for them using technologies we have developed as part our ongoing and previous projects. |
Collaborator Contribution | See above. For commercial reasons specific details of the project are confidential. |
Impact | The collaboration is in progress. It is too early to report outputs. |
Start Year | 2016 |